Patients with Duffy null status are more likely to experience misdiagnoses, unnecessary medical tests, and increased health ...

Kashiv BioSciences commercially launched Pexegra, a biosimilar referencing Neulasta, and Filra, a biosimilar referencing ...

The regulatory approval of the oral estrogen receptor antagonist is for patients whose cancer has an ESR1 mutation and has ...

Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified immunotherapeutics company, today announced that the company’s CEO ...

The range of autoimmune diseases treatable with chimeric antigen receptor (CAR) T-cell therapy could be much broader than ...

C4 Therapeutics' zinc finger protein-1 and 3 (IKZF1/3) degrader cemsidomide has demonstrated an overall response rate (ORR) ...

A research team from Umeå University, Sweden, in collaboration with Ghent University, Belgium, has made a groundbreaking discovery about how the body's first immune defense, neutrophils, orchestrate ...

During a live event, Raajit K. Rampal, MD, PhD, discussed ropeginterferon's potential to reduce JAK2 allele burden in ...

(OS) observed at 9 months; standard of care benchmark is ~47% -- 53% progression-free survival (PFS) observed at 9 months; ...

A team from the universities of Umeå and Ghent has discovered that neutrophils carefully control zinc levels to weaken and ...

Up to a quarter of patients with classical Hodgkin’s lymphoma (HL) are resistant or have disease relapse after first-line ...